patient compliance for their new protease inhibitor, Norvir (ritonavir)

June 1996

Abbott is sending out letters emphasizing patient compliance for their new protease inhibitor, Norvir (ritonavir).

The problem is that patients starting Norvir often develop nausea...diarrhea...and peripheral neuropathy. This may tempt them to stop the drug or cut back on the dose.

But maintaining therapeutic levels of Norvir is crucial...to suppress HIV and prevent the rapid development of resistance.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote